LGD-4033 (Ligandrol) Capsules

Buy LGD-4033 (Ligandrol) Capsules Online

Buy LGD-4033 (Ligandrol) Capsules are research-grade compounds designed for scientific studies, particularly in the field of selective androgen receptor modulators (SARMs). LGD-4033 is a nonsteroidal SARM that exhibits high affinity and selectivity for the androgen receptor, making it a subject of interest in research related to muscle wasting and osteoporosis.

Chemical Structure and Physical Properties

• Chemical Name: 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile
• Synonyms: LGD-4033, VK5211, Ligandrol
• Molecular Formula: C₁₄H₁₂F₆N₂O
• Molecular Weight: 338.3 g/mol
• CAS Number: 1165910-22-4
• Form: Capsules containing LGD-4033 in a suitable excipient
• Appearance: Capsules with white to off-white powder
• Purity: >99.0%
• Solubility: Soluble in DMSO; not soluble in water
• Storage Recommendations: Store at -20°C under dry conditions to maintain stability

Intended Use

LGD-4033 Capsules are intended strictly for laboratory research and analytical purposes. Researchers utilize this compound to study its pharmacodynamics, receptor binding affinities, and potential applications within the SARM class. This product is not intended for human or animal consumption.

Packaging and Shipping

• Packaging: Each capsule is securely packaged to maintain product integrity and confidentiality.
• Shipping: Orders are shipped under ambient temperature as non-hazardous chemicals. This product is stable for a few weeks during ordinary shipping and time spent in customs.

Legal and Compliance Disclaimer

• Research Use Only: LGD-4033 Capsules are sold strictly for laboratory research and analytical purposes.
• Legal Status: The legal status of LGD-4033 varies by jurisdiction. Customers are responsible for verifying the legal status in their respective countries before ordering.
• Age Restriction: Purchasers must be 18 years or older.
• Safety Compliance: Appropriate laboratory personal protective equipment (PPE) should be used when handling this compound. Avoid direct skin contact and inhalation. Store in a cool, dry place away from direct sunlight.

Hazard Statements

• Hazard Symbols: ⚠️
• Hazard Statements:
  • H302: Harmful if swallowed.
  • H315: Causes skin irritation.
  • H319: Causes serious eye irritation.
  • H335: May cause respiratory irritation.
• Precautionary Statements:
  • P261: Avoid breathing dust/fume/gas/mist/vapors/spray.
  • P264: Wash hands thoroughly after handling.
  • P270: Do not eat, drink, or smoke when using this product.
  • P271: Use only outdoors or in a well-ventilated area.
  • P280: Wear protective gloves/protective clothing/eye protection/face protection.
  • P301+P312: IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell.
  • P302+P352: IF ON SKIN: Wash with plenty of soap and water.
  • P304+P340: IF INHALED: Remove person to fresh air and keep comfortable for breathing.
  • P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing.
  • P403+P233: Store in a well-ventilated place. Keep container tightly closed.
  • P405: Store locked up.
  • P501: Dispose of contents/container in accordance with local regulations.

Development and History

LGD-4033 was developed by Ligand Pharmaceuticals and was first described in the literature in 2010. On the basis of a favorable preclinical profile, phase 1 clinical trials of LGD-4033 began in 2009. The results of a single-dose phase 1 clinical trial were published as a conference abstract in 2010, and the findings of a multi-dose phase 1 trial were published as a journal article in 2013. A third phase 1 trial was also conducted. By 2012, a phase 2 trial of LGD-4033 for the treatment of muscle wasting related to cancer cachexia, acute rehabilitation (e.g., hip fracture), and acute illness was being prepared by Ligand Pharmaceuticals. On May 22, 2014, Viking Therapeutics licensed the developmental rights of LGD-4033 from Ligand Pharmaceuticals and intended to advance the compound into mid-to-late-stage clinical trials. The phase 2 study of LGD-4033 for muscle wasting was finally initiated in November 2016 and was completed with results reported in 2017 and 2018. As of March 2023, LGD-4033 (VK5211) continues to be under development by Viking Therapeutics and continues to be in phase 2 clinical trials for treatment of muscle atrophy and hip fracture.

Ordering Information

LGD-4033 Capsules are available for purchase through various research chemical suppliers. Ensure that you are ordering from a reputable source that complies with all legal and safety regulations. Before placing an order, verify the legal status of LGD-4033 in your jurisdiction and ensure that you meet all necessary requirements for purchasing research chemicals.

Please note that this product is not intended for human or animal consumption and should only be handled by qualified professionals in a controlled laboratory setting.